PriceTargets.com logo

Emmaus Life Sciences - EMMA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.10 As of 04/25/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for EMMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Emmaus Life Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EMMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EMMA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Emmaus Life Sciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.10.

This chart shows the closing price for EMMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Emmaus Life Sciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/27/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/24/2019Dawson JamesDowngradeBuy ➝ Neutral
(Data available from 4/26/2019 forward)

News Sentiment Rating

-0.15 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/29/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/28/2023
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/27/2024
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/27/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/26/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Emmaus Life Sciences logo
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Read More

Today's Range

Now: $0.10
Low: $0.10
High: $0.10

50 Day Range

MA: $0.11
Low: $0.09
High: $0.13

52 Week Range

Now: $0.10
Low: $0.05
High: $0.34

Volume

1 shs

Average Volume

4,059 shs

Market Capitalization

$6.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.61

Frequently Asked Questions

What sell-side analysts currently cover shares of Emmaus Life Sciences?

The following sell-side analysts have issued stock ratings on Emmaus Life Sciences in the last twelve months:
View the latest analyst ratings for EMMA.

What is the current price target for Emmaus Life Sciences?

0 Wall Street analysts have set twelve-month price targets for Emmaus Life Sciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Emmaus Life Sciences in the next year.
View the latest price targets for EMMA.

What is the current consensus analyst rating for Emmaus Life Sciences?

Emmaus Life Sciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for EMMA.

What other companies compete with Emmaus Life Sciences?

Other companies that are similar to Emmaus Life Sciences include Ayala Pharmaceuticals, Hoth Therapeutics, Sonnet BioTherapeutics, Xenetic Biosciences and Avenue Therapeutics. Learn More about companies similar to Emmaus Life Sciences.

How do I contact Emmaus Life Sciences' investor relations team?

Emmaus Life Sciences' physical mailing address is 21250 Hawthorne Boulevard Suite 800, Torrance CA, 90503. The company's listed phone number is (310) 214-0065 and its investor relations email address is [email protected]. The official website for Emmaus Life Sciences is www.emmausmedical.com. Learn More about contacing Emmaus Life Sciences investor relations.